Conscience

Partner

Conscience is a non-profit focused on addressing market failure in drug development. Based in Canada, and launched in partnership with the Structural Genomics Consortium, the organization is supported with a $49M investment from the Government of Canada, and led by some of the industry’s most respected academics, researchers, industry and community leaders.

Launched in 2023 with $105 million in new funding to support network building, challenges, and direct investment in promising open science drug discovery, the Conscience Network brings people and organizations together to turn science into a team sport. Our staff and board combine deep expertise in drug development with community and network development for collaboration in open communities of practice.

Conscience is currently focused on three areas of work:

1. Network development, engagement, and support
2. Challenges for discovery and benchmarking
3. Investment in promising drug discovery projects